Delcath Systems, Inc. announced the presentation of new subgroup analysis data from the phase 3 FOCUS trial of Hepzato Kit (m ...

NanoVation Therapeutics, a Vancouver company co-founded by biotech magnate Pieter Cullis, has struck a partnership with ...

Objective We performed a meta-analysis of observational studies to quantify the magnitude of the association between non-alcoholic fatty liver disease (NAFLD) and risk of extrahepatic cancers. Design ...

Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Extrahepatic Bile Duct Cancer. According to GlobalData, Phase II drugs for Extrahepatic Bile Duct Cancer ...

A study led by Manuel Vázquez Carrera, group leader at the Diabetes and Associated Metabolic Diseases Networking Biomedical ...

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on liver-directed cancer therapies, today announced the presentation of new subgroup analysis data from the FOCUS Phase ...

NanoVation will receive $600m in upfront cash and potential milestone payments, as well as tiered royalties on future product ...

HB-002.1T is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase I for Extrahepatic Bile Duct Cancer. According to GlobalData, Phase I drugs for Extrahepatic Bile Duct ...

A study led by Manuel Vázquez Carrera, group leader at the Diabetes and Associated Metabolic Diseases Networking Biomedical ...

NAFLD is a multisystem disease where systemic insulin resistance and related metabolic dysfunction play a pathogenic role in the development of NAFLD and its most relevant liver-related morbidities ...

The agreement with NanoVation marks the second big recent deal that a B.C. biotech startup has struck with the Danish ...